Few compounds in metabolic research have attracted as much attention in recent years as the triple-agonist peptides known in the research field as GLP-3. By engaging three hormone receptors with a single molecule, this class has changed how scientists think about energy balance, glucose regulation, and liver metabolism.
This article explains what GLP-3 is, how it works at the receptor level, where it is being applied in laboratory research, and what the published science has revealed so far.
All compounds discussed here are research chemicals intended strictly for in-vitro laboratory use. Nothing in this article is medical advice.
What Is GLP-3?
“GLP-3” is the name commonly used in the research peptide field for triple-agonist compounds that activate three receptors at once:
- The GLP-1 receptor (glucagon-like peptide-1)
- The GIP receptor (glucose-dependent insulinotropic polypeptide)
- The glucagon receptor
The most extensively studied molecule in this class is retatrutide (LY3437943). It is important to note that “GLP-3” is a shorthand label rather than the name of a natural hormone — there is no endogenous “glucagon-like peptide-3.” The “3” refers to the three receptor targets.
GLP-3 represents the third generation of incretin-based research compounds, following single-receptor GLP-1 agonists and dual agonists that pair GLP-1 with either GIP or glucagon activity.
Mechanism of Action: How GLP-3 Works
Three Receptors, One Molecule
All three target receptors belong to the class B G protein-coupled receptor (GPCR) family. When activated, each primarily signals through the Gs protein, raising intracellular cyclic AMP (cAMP) and triggering downstream pathways. Although they share this signaling route, the receptors are expressed in different tissues and produce distinct physiological effects:
| Receptor | Key Tissues | Primary Effects Studied |
| GLP-1 | Pancreas, brain, gut | Glucose-dependent insulin secretion, reduced glucagon release, slower gastric emptying, appetite signaling |
| GIP | Pancreas, adipose tissue, brain | Insulin secretion, lipid handling in fat tissue, possible role in appetite regulation |
| Glucagon | Liver, adipose tissue | Increased energy expenditure, hepatic fat oxidation, glucose production |
Why Combine Them?
The logic of triple agonism is complementary action. GLP-1 and GIP activity support insulin secretion and reduce food intake. Glucagon receptor activity adds something the other two lack: it raises energy expenditure and promotes fat oxidation in the liver.
On its own, glucagon also raises blood glucose. In a triple agonist, the insulin-promoting effects of GLP-1 and GIP activity are thought to counterbalance this, allowing researchers to study glucagon’s metabolic benefits without its glucose-raising effect dominating.
A Deliberately Unbalanced Profile
One of the most important insights from the pharmacology literature is that retatrutide does not activate all three receptors equally. Published preclinical characterization reported that it is more potent than native GIP at the human GIP receptor, while being less potent than the native hormones at the GLP-1 and glucagon receptors.
This balance is intentional. Too much glucagon activity could push glucose upward, while too little would lose the energy-expenditure benefit. The relative potency at each receptor is one of the most actively studied variables in this field.
Built for Stability
Native incretin hormones are degraded by the enzyme DPP-4 within minutes. Retatrutide’s peptide backbone includes modified amino acids that resist this breakdown, and it carries a fatty acid side chain that binds to albumin in circulation. Together, these features extend its half-life to several days in clinical studies — which also makes it a practical molecule for longer-duration experimental models.
Research Applications
Because GLP-3 engages three interacting pathways, it has become a useful tool across several areas of metabolic research.
1. Energy Balance and Body Weight
The most widely reported research on retatrutide concerns body weight. In a phase 2 trial published in the New England Journal of Medicine in 2023, participants in the highest-dose groups lost an average of about 24% of body weight over 48 weeks. For researchers, this raises a central mechanistic question: how much of the effect comes from reduced food intake, and how much from increased energy expenditure driven by glucagon receptor activity?
2. Glucose Metabolism
A separate phase 2 study in participants with type 2 diabetes, published in The Lancet in 2023, reported meaningful reductions in HbA1c alongside weight loss. This makes GLP-3 compounds valuable for studying how multi-receptor signaling affects insulin secretion, insulin sensitivity, and glucose production.
3. Liver Fat and Hepatic Metabolism
Liver research is one of the most distinctive areas for triple agonists. Because the glucagon receptor is highly expressed in the liver, GLP-3 compounds are studied for their effects on hepatic fat. Substudy data from retatrutide trials reported substantial reductions in liver fat content, with many participants reaching normal levels. This has made the class of particular interest in research on metabolic dysfunction-associated steatotic liver disease (MASLD).
4. Receptor Pharmacology
Beyond outcomes, GLP-3 is a valuable tool for basic receptor science. Laboratories use triple agonists alongside single and dual agonists to study receptor cross-talk, signaling bias, receptor internalization, and how combined activation differs from activating each receptor alone.
5. Adipose Tissue Biology
Both GIP and glucagon receptors are present in fat tissue. In-vitro and preclinical models allow researchers to examine how triple agonism influences lipolysis, lipid storage, and adipocyte function.
Key Scientific Insights So Far
Several themes have emerged from the published research:
- Multi-receptor effects appear greater than single-receptor effects. Each step from single to dual to triple agonism has been associated with larger metabolic changes in published studies.
- Glucagon activity adds a distinct dimension. It contributes energy expenditure and liver fat effects that GLP-1 and GIP activity alone do not strongly provide.
- Receptor balance matters as much as receptor number. The relative potency at each target shapes the overall profile.
- Effects were dose-dependent. Clinical studies reported both efficacy and tolerability effects — most commonly gastrointestinal — that increased with dose, along with observations such as heart-rate changes that remain an active area of study.
- Long-term data is still developing. Larger phase 3 programs have been underway to examine durability and broader outcomes, so many questions remain open.
Open Questions for Researchers
Despite rapid progress, important gaps remain:
- How does each receptor contribute to the combined effect, and can those contributions be cleanly separated?
- How does signaling balance change with prolonged exposure?
- What are the effects on lean mass, muscle, and bone?
- How do triple agonists act on tissues beyond the pancreas, liver, and fat — including the brain, heart, and kidney?
These questions are well suited to controlled laboratory research, where individual variables can be isolated and measured.
Working with GLP-3 in the Lab
Because GLP-3 compounds are long, modified peptide sequences, material quality directly affects experimental reliability. Researchers should look for lot-specific HPLC purity data, mass spectrometry confirmation of identity, and a Certificate of Analysis that matches the vial received. You can read more about how we verify every batch on our About page.
Storage matters too. Lyophilized peptide should be kept frozen at -20°C, while reconstituted material should be held at 2–8°C and divided into single-use aliquots to avoid repeated freeze-thaw cycles.
Conclusion
GLP-3 triple agonists represent the most advanced stage yet in incretin-based research. By combining GLP-1, GIP, and glucagon receptor activity in a single, stable molecule, they give scientists a way to study how gut, pancreatic, and liver signals work together to regulate metabolism. The published findings are striking, but many of the most interesting mechanistic questions are only beginning to be answered.
To explore lot-tested GLP-3 research peptide materials, browse our verified research peptide catalog, or contact our team to request a COA or ask about availability for your institution.